In the past week, RIGL stock has gone down by -10.79%, with a monthly decline of -16.91% and a quarterly plunge of -29.11%. The volatility ratio for the week is 9.20%, and the volatility levels for the last 30 days are 8.70% for Rigel Pharmaceuticals The simple moving average for the past 20 days is -3.61% for RIGL’s stock, with a -37.68% simple moving average for the past 200 days.

Is It Worth Investing in Rigel Pharmaceuticals (NASDAQ: RIGL) Right Now?

Additionally, the 36-month beta value for RIGL is 0.71. There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 0 rating it as “overweight,” 4 rating it as “hold,” and 0 rating it as “sell.”

The average price predicted by analysts for RIGL is $4.25, which is $3.46 above the current price. The public float for RIGL is 171.70M and currently, short sellers hold a 2.11% ratio of that float. The average trading volume of RIGL on November 16, 2023 was 1.01M shares.

RIGL) stock’s latest price update

The stock price of Rigel Pharmaceuticals (NASDAQ: RIGL) has dropped by -6.60 compared to previous close of 0.85. Despite this, the company has seen a fall of -10.79% in its stock price over the last five trading days. Seeking Alpha reported 2023-11-07 that Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL ) Q3 2023 Earnings Conference Call November 7, 2023 4:30 PM ET Company Participants Ray Furey – Executive Vice President, General Counsel & Corporate Secretary Raul Rodriguez – President & Chief Executive Officer Dean Schorno – Chief Financial Officer Dave Santos – EVP & Chief Commercial Officer Conference Call Participants Joe Pantginis – H.C. Wainwright Operator Greetings, and welcome to Rigel Pharmaceuticals Financial Conference Call for the Third Quarter of 2023.

Analysts’ Opinion of RIGL

Many brokerage firms have already submitted their reports for RIGL stocks, with Piper Sandler repeating the rating for RIGL by listing it as a “Neutral.” The predicted price for RIGL in the upcoming period, according to Piper Sandler is $2 based on the research report published on April 03, 2023 of the current year 2023.

RIGL Trading at -17.89% from the 50-Day Moving Average

After a stumble in the market that brought RIGL to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -61.08% of loss for the given period.

Volatility was left at 8.70%, however, over the last 30 days, the volatility rate increased by 9.20%, as shares sank -16.36% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -29.11% lower at present.

During the last 5 trading sessions, RIGL fell by -10.79%, which changed the moving average for the period of 200-days by -51.59% in comparison to the 20-day moving average, which settled at $0.8160. In addition, Rigel Pharmaceuticals saw -47.07% in overturn over a single year, with a tendency to cut further losses.

Insider Trading

Reports are indicating that there were more than several insider trading activities at RIGL starting from RODRIGUEZ RAUL R, who sale 20,340 shares at the price of $1.75 back on Feb 06. After this action, RODRIGUEZ RAUL R now owns 1,680,713 shares of Rigel Pharmaceuticals, valued at $35,595 using the latest closing price.

Dummer Wolfgang, the EVP & CMO of Rigel Pharmaceuticals, sale 5,389 shares at $1.66 during a trade that took place back on Feb 02, which means that Dummer Wolfgang is holding 72,459 shares at $8,946 based on the most recent closing price.

Stock Fundamentals for RIGL

Current profitability levels for the company are sitting at:

The net margin for Rigel Pharmaceuticals stands at -48.71. The total capital return value is set at -122.04, while invested capital returns managed to touch -150.47. Equity return is now at value -699.05, with -21.16 for asset returns.

When we switch over and look at the enterprise to sales, we see a ratio of 0.99, with the company’s debt to enterprise value settled at 0.17. The receivables turnover for the company is 4.31 and the total asset turnover is 0.80. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.78.


In conclusion, Rigel Pharmaceuticals (RIGL) has seen bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.